Koers MEDIGENE NA Swiss Exchange
Aandelen
OXMDGG
DE0005020903
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- EUR | - |
Omzet 2024 * | 10,6 mln. 11,34 mln. | Omzet 2025 * | 6,95 mln. 7,44 mln. | Marktkapitalisatie | 37,59 mln. 40,23 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -11,77 mln. | Nettowinst (verlies) 2025 * | -17 mln. -18,19 mln. | EV/omzet 2024 * | 5,15 x |
Nettoschuld 2024 * | 17 mln. 18,19 mln. | Nettoschuld 2025 * | 14 mln. 14,98 mln. | EV/omzet 2025 * | 7,42 x |
K/w-verhouding 2024 * |
-3,45
x | K/w-verhouding 2025 * |
-2,28
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,05% |
Recentste transcriptie over MEDIGENE NA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 25-07-22 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-14 |
Pamela Keck
IRC | Investor Relations Contact | - | 01-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 66 | 12-08-16 | |
Frank Mathias
BRD | Director/Board Member | 62 | 15-05-18 |
Anthony Man
BRD | Director/Board Member | 68 | 16-12-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 112 mld. | |
-12,75% | 22,22 mld. | |
+5,07% | 22,94 mld. | |
-39,94% | 16,87 mld. | |
-9,86% | 17,02 mld. | |
-14,97% | 16,88 mld. | |
+2,80% | 13,63 mld. | |
+27,39% | 11,61 mld. |
- Beurs
- Aandelen
- Koers MDG1
- Koers OXMDGG